We are excited to be in Philadelphia for the American Heart Association conference. Our Phase 2 Open Label Extension data examining patients with ATTR-CM will be presented tonight. ATTR-CM is a progressive & fatal disease that is an under-recognized cause of heart failure. #AHA19
Eidos Therapeutics was honored last night in Boston with the #CAREAwards2019 for Excellence in Rare Disease Drug Development. We are currently enrolling in the ATTRibute-CM trial with AG10 for patients with ATTR Amyloid Cardiomyopathy. https://t.co/XPBeIH46zb